Genetic and phenotypic characterization of Parkinson's disease at the clinic-wide level.
Journal
NPJ Parkinson's disease
ISSN: 2373-8057
Titre abrégé: NPJ Parkinsons Dis
Pays: United States
ID NLM: 101675390
Informations de publication
Date de publication:
03 May 2024
03 May 2024
Historique:
received:
11
08
2023
accepted:
19
03
2024
medline:
4
5
2024
pubmed:
4
5
2024
entrez:
3
5
2024
Statut:
epublish
Résumé
Observational studies in Parkinson's disease (PD) deeply characterize relatively small numbers of participants. The Molecular Integration in Neurological Diagnosis Initiative seeks to characterize molecular and clinical features of every PD patient at the University of Pennsylvania (UPenn). The objectives of this study are to determine the feasibility of genetic characterization in PD and assess clinical features by sex and GBA1/LRRK2 status on a clinic-wide scale. All PD patients with clinical visits at the UPenn PD Center between 9/2018 and 12/2022 were eligible. Blood or saliva were collected, and a clinical questionnaire administered. Genotyping at 14 GBA1 and 8 LRRK2 variants was performed. PD symptoms were compared by sex and gene groups. 2063 patients were approached and 1,689 (82%) were enrolled, with 374 (18%) declining to participate. 608 (36%) females were enrolled, 159 (9%) carried a GBA1 variant, and 44 (3%) carried a LRRK2 variant. Compared with males, females across gene groups more frequently reported dystonia (53% vs 46%, p = 0.01) and anxiety (64% vs 55%, p < 0.01), but less frequently reported cognitive impairment (10% vs 49%, p < 0.01) and vivid dreaming (53% vs 60%, p = 0.01). GBA1 variant carriers more frequently reported anxiety (67% vs 57%, p = 0.04) and depression (62% vs 46%, p < 0.01) than non-carriers; LRRK2 variant carriers did not differ from non-carriers. We report feasibility for near-clinic-wide enrollment and characterization of individuals with PD during clinical visits at a high-volume academic center. Clinical symptoms differ by sex and GBA1, but not LRRK2, status.
Identifiants
pubmed: 38702337
doi: 10.1038/s41531-024-00690-6
pii: 10.1038/s41531-024-00690-6
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
ID : NS115139, AG072979, AG062418
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
ID : NS114167
Informations de copyright
© 2024. The Author(s).
Références
Tanner, C. M. & Goldman, S. M. Epidemiology of movement-disorders. Curr. Opin. Neurol. 7, 340–345 (1994).
doi: 10.1097/00019052-199408000-00011
pubmed: 7952243
de Lau, L. M. & Breteler, M. M. Epidemiology of Parkinson’s disease. Lancet Neurol. 5, 525–535 (2006).
doi: 10.1016/S1474-4422(06)70471-9
pubmed: 16713924
Marras, C. et al. Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis. 4, 21 (2018).
doi: 10.1038/s41531-018-0058-0
pubmed: 30003140
pmcid: 6039505
Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30, 1591–1601 (2015).
doi: 10.1002/mds.26424
pubmed: 26474316
Martinez-Martin, P., Rodriguez-Blazquez, C., Kurtis, M. M. & Chaudhuri, K. R. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov. Disord. 26, 399–406 (2011).
doi: 10.1002/mds.23462
pubmed: 21264941
Chaudhuri, K. R., Healy, D. G. & Schapira, A. H. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 5, 235–245 (2006).
doi: 10.1016/S1474-4422(06)70373-8
pubmed: 16488379
Picillo, M. et al. Sex-related longitudinal change of motor, non-motor, and biological features in early Parkinson’s disease. J. Parkinsons Dis. 12, 421–436 (2022).
doi: 10.3233/JPD-212892
pubmed: 34744052
pmcid: 8842783
Solla, P. et al. Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson’s disease. J. Neurol. Sci. 323, 33–39 (2012).
doi: 10.1016/j.jns.2012.07.026
pubmed: 22935408
Martinez-Martin, P. et al. Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease. J. Neurol. 259, 1639–1647 (2012).
doi: 10.1007/s00415-011-6392-3
pubmed: 22237822
Petrucci, S. et al. GBA‐related Parkinson’s disease: dissection of genotype–phenotype correlates in a large italian cohort. Mov. Disord. 35, 2106–2111 (2020).
doi: 10.1002/mds.28195
pubmed: 32658388
Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N. Eng. J. Med. 361, 1651–1661 (2009).
doi: 10.1056/NEJMoa0901281
Mata, I. F. et al. GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson’s disease. Mov. Disord. 31, 95–102 (2016).
doi: 10.1002/mds.26359
pubmed: 26296077
Alcalay, R. N. et al. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson’s disease. Parkinsonism Relat. Disord. 21, 106–110 (2015).
doi: 10.1016/j.parkreldis.2014.09.033
pubmed: 25434972
Macleod, A. D. et al. Age-related selection bias in Parkinson’s disease research: are we recruiting the right participants? Parkinsonism Relat. Disord. 55, 128–133 (2018).
doi: 10.1016/j.parkreldis.2018.05.027
pubmed: 29871791
Hamedani, A. G. et al. Adjusting for underrepresentation reveals widespread underestimation of Parkinson’s disease symptom burden. Mov. Disord. https://doi.org/10.1002/mds.29507 (2023).
Aamodt, W. W., Willis, A. W. & Dahodwala, N. Racial and ethnic disparities in Parkinson disease. Neurol. Clin. Pract. 13, e200138 (2023).
doi: 10.1212/CPJ.0000000000200138
pubmed: 37064587
pmcid: 10101714
Schneider, M. G. et al. Minority enrollment in Parkinson’s disease clinical trials. Parkinsonism Relat. Disord. 15, 258–262 (2009).
doi: 10.1016/j.parkreldis.2008.06.005
pubmed: 18693062
Tropea, T. F. et al. Whole clinic research enrollment in Parkinson’s disease: the Molecular Integration in Neurological Diagnosis (MIND) study. J. Parkinsons Dis. 11, 757–765 (2021).
doi: 10.3233/JPD-202406
pubmed: 33492247
pmcid: 8058284
Morley, J. F. et al. Genetic influences on cognitive decline in Parkinson’s disease. Mov. Disord. 27, 512–518 (2012).
doi: 10.1002/mds.24946
pubmed: 22344634
pmcid: 3323737
Marek, K. et al. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95, 629–635 (2011).
doi: 10.1016/j.pneurobio.2011.09.005
pmcid: 9014725
Tropea, T. F. et al. APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson’s disease. Mov. Disord. 33, 289–297 (2018).
doi: 10.1002/mds.27204
pubmed: 29168904
Yarnall, A. J. et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 82, 308–316 (2014).
doi: 10.1212/WNL.0000000000000066
pubmed: 24363137
pmcid: 3929202
Mollenhauer, B. et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology 81, 1226–1234 (2013).
doi: 10.1212/WNL.0b013e3182a6cbd5
pubmed: 23997153
Williams-Gray, C. H. et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J. Neurol. Neurosurg. Psychiatry 84, 1258–1264 (2013).
doi: 10.1136/jnnp-2013-305277
pubmed: 23781007
Smolensky, L. et al. Fox insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson’s disease. Sci. Data 7, 67 (2020).
doi: 10.1038/s41597-020-0401-2
pubmed: 32094335
pmcid: 7039948
Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091–1102 (2019).
doi: 10.1016/S1474-4422(19)30320-5
pubmed: 31701892
pmcid: 8422160
Cerri, S., Mus, L. & Blandini, F. Parkinson’s disease in women and men: what’s the difference? J. Parkinsons Dis. 9, 501–515 (2019).
doi: 10.3233/JPD-191683
pubmed: 31282427
pmcid: 6700650
Russillo, M. C. et al. Sex differences in Parkinson’s disease: from bench to bedside. Brain Sci. 12, 917 (2022).
doi: 10.3390/brainsci12070917
pubmed: 35884724
pmcid: 9313069
Orr-Urtreger, A. et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: Is there a gender effect? Neurology 69, 1595–1602 (2007).
doi: 10.1212/01.wnl.0000277637.33328.d8
pubmed: 17938369
Marder, K. et al. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology 85, 89–95 (2015).
doi: 10.1212/WNL.0000000000001708
pubmed: 26062626
pmcid: 4501942
Alcalay, R. N. et al. Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations. Mov. Disord. 28, 1966–1971 (2013).
doi: 10.1002/mds.25647
pubmed: 24243757
Malek, N. et al. Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study. J. Neurol. Neurosurg. Psychiatry 89, 702–709 (2018).
doi: 10.1136/jnnp-2017-317348
pubmed: 29378790
Toffoli, M. et al. Phenotypic effect of GBA1 variants in individuals with and without Parkinson’s disease: the RAPSODI study. Neurobiol. Dis. 188, 106343 (2023).
doi: 10.1016/j.nbd.2023.106343
pubmed: 37926171
Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 132, 1783–1794 (2009).
doi: 10.1093/brain/awp044
pubmed: 19286695
pmcid: 2702833
Toledo, J. B. et al. A platform for discovery: the University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimer’s Dementia 10, 477–484.e1 (2014).
doi: 10.1016/j.jalz.2013.06.003
pubmed: 23978324
Racine, J. S., RStudio: A. Platform-Independent I. D. E. for R and Sweave. J. Appl. Econom. 27, 167–172 (2012).
doi: 10.1002/jae.1278
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289–300 (1995).
doi: 10.1111/j.2517-6161.1995.tb02031.x
Tropea, T. F. et al. Molecular Integration in Neurological Diagnosis (MIND) Parkinson’s Disease Inception Cohort Study Protocol. PROTOCOL (Version 1) available at Protocol Exchange [ https://doi.org/10.21203/rs.3.pex-2505/v1 ] (2024).